Navigating 4 Analyst Ratings For Dianthus Therapeutics
Portfolio Pulse from Benzinga Insights
Dianthus Therapeutics (NASDAQ:DNTH) received mixed analyst ratings over the last quarter, with 2 bullish and 2 somewhat bullish ratings. The average 12-month price target increased by 11.54% to $43.5. Analysts' actions include maintaining, lowering, and announcing new ratings with price targets ranging from $36.00 to $58.00.
August 12, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dianthus Therapeutics received mixed analyst ratings with an average 12-month price target increase of 11.54% to $43.5. Analysts' price targets range from $36.00 to $58.00.
The mixed analyst ratings and the increase in the average 12-month price target suggest a positive short-term outlook for DNTH. The range of price targets indicates varying levels of confidence among analysts, but the overall trend is upward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100